ALNY
Alnylam Pharmaceuticals, Inc.
34
Building
Alnylam Pharmaceuticals is driven by RNAi technology innovation and rapid revenue growth.
The thesis
Alnylam Pharmaceuticals develops RNAi-based treatments, benefiting from 66.9% YoY revenue growth and a 7972.0% gross margin. The company's conviction score is 30/100, indicating medium conviction. Analyst consensus is BUY, despite a high P/E of 42.2x and a negative DCF intrinsic value of $-1419. The high revenue growth and gross margin make the setup interesting.
Why now
The company's strong revenue growth and high gross margin make it an attractive investment opportunity amidst a risk-off rotation. The 66.9% YoY revenue growth is a key catalyst.
What to watch
Investors should monitor the company's revenue growth trajectory and gross margin stability over the next quarter. Upcoming pipeline updates and regulatory decisions will also be crucial in confirming or denying the thesis.
Key risks
The high P/E ratio of 42.2x poses a valuation risk, while the negative DCF intrinsic value of $-1419 raises concerns about the company's long-term profitability. Execution risk is also present, given the company's reliance on innovative RNAi technology.
Theme exposure
Healthcare, Biotech & Devices
DirectAlnylam Pharmaceuticals, Inc. operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.
This brief is generated from our intelligence layers. Treat it as a starting point, not a final word.
Market intelligence only. Not financial advice. Not a recommendation.